Three-Dimensional Motor Nerve Organoid Generation
September 24th, 2020
10.2K views
This protocol provides a comprehensive procedure to fabricate human iPS cell-derived motor nerve organoid through spontaneous assembly of a robust bundle of axons extended from a spheroid in a tissue culture chip.
Overview
This study presents a protocol for generating human iPS cell-derived motor nerve organoids through the spontaneous assembly of axons from a neuronal spheroid in a custom PDMS microculture chip. The platform allows for the investigation of axon bundle development and motor neuron diseases, facilitating efficient drug screening and testing.
Key Study Components
Area of Science
- Neuroscience
- Stem Cell Biology
- Organoid Technology
Background
- Motor nerve organoids provide a more physiological model compared to traditional in vitro systems.
- Understanding motor neuron diseases like Amyotrophic Lateral Sclerosis (ALS) is crucial for developing effective therapies.
- This protocol utilizes human iPS cells to generate a relevant biological model for research.
Purpose of Study
- To fabricate motor nerve organoids for studying axon development.
- To enhance drug screening for motor neuron diseases using a more accurate cellular environment.
- To provide a detailed methodology for generating and utilizing these models in research.
Methods Used
- The main platform used is a PDMS microfluidic chip designed for tissue culture.
- The biological model consists of motor neurons differentiated from human iPS cells.
- The protocol involves several key steps over a period of approximately two to three weeks.
- Cultures are maintained in a CO2 incubator, with specific media changes outlined for differentiation.
- Motor neuron spheroids are introduced into the microchannel to facilitate axon bundle formation.
Main Results
- Axons grow from motor neuron spheroids and assemble into organized bundles through axo-axonal interactions.
- Over 60% of differentiated cells express the motor neuron marker HB9, indicating successful differentiation.
- The model achieves functional maturation within 12 to 14 days post-differentiation, with key cellular changes noted over time.
- Motor nerve organoids show promise for biological analysis relevant to motor neuron diseases.
Conclusions
- This study demonstrates a reliable method for generating motor nerve organoids for research and pharmaceutical applications.
- It highlights the significance of using human iPS cells in disease modeling and drug screening.
- The findings contribute to a deeper understanding of neuronal mechanisms and the development of therapeutics.
Frequently Asked Questions
What are the advantages of using motor nerve organoids?
Motor nerve organoids provide a more physiologically relevant environment for studying motor neuron diseases, enhancing drug screening and testing efficacy.
How is the motor neuron differentiation achieved?
Differentiation is achieved by seeding iPS cells in specific culture media and following a detailed timeline of media changes and supplements over several days.
What types of outcomes are assessed with this method?
The method enables evaluation of cell differentiation, axon growth, and molecular markers of motor neurons, aiding in the study of neuronal development and diseases.
Can this method be adapted for different applications?
Yes, this protocol can be tailored to explore various aspects of neuronal biology and drug testing, making it versatile for research applications.
What are the key limitations of this protocol?
While this method provides significant insights, limitations include the complexity of maintaining culture conditions and the potential for variability in organoid formation.
How does the PDMS microfluidic chip contribute to the study?
The PDMS microfluidic chip facilitates the controlled environment for 3D cell culture, promoting the spontaneous assembly of axon bundles.
Executive Industry Relevance
Motor nerve organoids derived from human iPS cells provide a physiologically relevant 3D model for studying axon fascicle formation and dysfunction, addressing a critical gap in neurodegenerative disease research. This platform enables mechanistic de-risking of therapeutic targets by recapitulating axon bundle assembly in a controlled microenvironment, supporting predictive confidence in early discovery. The model facilitates drug screening for motor neuron diseases such as ALS by offering improved translational relevance over traditional 2D cultures.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses related to axon fascicle development and stability in a human-relevant 3D system.
- Operational Value: Supports functional target validation through quantification of axon bundle formation and maturation over defined timelines.
- Predictive Value: Contributes to portfolio triage by modeling early pathophysiological events in motor neuron diseases.
Screening & Assay Development
- Scientific Value: Generates axon bundles suitable for biochemical assays requiring substantial material, enabling target engagement and pathway modulation studies.
- Operational Value: Provides standardized, reproducible axon fascicle formation within microfluidic channels, supporting assay scalability and cross-lab consistency.
- Assay Readiness: Facilitates compound screening by allowing retrieval of organoids for fixation, dissection, calcium imaging, or multi-electrode array analysis.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery and preclinical validation by modeling human axon fascicle biology in a disease-relevant context.
- Mechanistic De-risking: Allows investigation of axon bundle formation mechanisms, reducing ambiguity in target pathways for motor neuron therapeutics.
- Biomarker Alignment: Enables assessment of motor neuron markers (HB9, SMI32) and absence of dendritic markers, supporting phenotypic validation in preclinical models.
Pipeline & Workflow Integration
The motor nerve organoid platform integrates into the discovery continuum from target validation through lead identification to preclinical assessment, enabling iterative refinement of therapeutic candidates based on axon phenotype.
- Discovery Biology: Supports hypothesis testing on axon fascicle formation and stability using a human iPS-derived 3D model with spontaneous axon bundle assembly.
- Screening: Delivers axon bundles amenable to biochemical and functional readouts, enabling compound library screening in a physiologically contextualized system.
- Analytics: Provides quantitative outputs including axon elongation kinetics, marker expression (HB9, SMI32), and electrophysiological potential via multi-electrode array or calcium imaging.
- Translational Research: Connects early discovery to preclinical continuity by modeling human axon pathology relevant to motor neuron disease progression.
- Enterprise Reuse: Establishes a reusable platform for axon biology investigation, adaptable across multiple targets and disease models in motor neuron research.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence in target validation by reducing mechanistic ambiguity in axon fascicle biology.
- Operational Value: Ensures reproducibility through standardized microfluidic chip fabrication and defined differentiation protocols.
- Strategic Value: Improves go/no-go decision-making by providing early phenotypic readouts linked to motor neuron disease mechanisms.
- Portfolio Impact: Enables risk-adjusted prioritization of compounds based on effects on axon bundle formation and maturation.
Implementation Considerations
- Requires expertise in stem cell differentiation, microfluidic device handling, and 3D tissue culture techniques.
- Dependent on access to photolithography equipment for SU-8 patterning and PDMS molding for chip fabrication.
- Necessitates standardized training for consistent spheroid transfer, medium exchange, and axon bundle recovery across teams.
- Adaptation to other neuronal subtypes may require modification of differentiation factors and channel geometry.
- Practical limitations include the two- to three-week timeline for axon bundle maturation and potential variability in spheroid positioning within the chip.
Biopharma FAQs
Why is axon bundle formation critical for target validation in motor neuron disease models?
Axon bundle formation reflects the structural and functional maturation of motor neurons, providing a phenotypic readout for assessing target engagement in disease-relevant contexts. Its quantification enables objective comparison across genetic or pharmacological conditions, supporting mechanistic de-risking of therapeutic hypotheses.
How does isolation of the motor neuron spheroid as an independent variable improve discovery pipeline efficiency?
Isolating the motor neuron spheroid allows researchers to study axon outgrowth and fascicle assembly as a dependent variable, minimizing confounding variables from heterogeneous cultures. This controlled approach enhances reproducibility and enables clear attribution of phenotypic changes to specific interventions.
What quantitative measurements of axon elongation and bundling enable compound screening decisions?
Axon elongation into the microchannel and time to form a single bundle provide quantifiable metrics for assessing compound effects on neurite outgrowth and axo-axonal interactions. These measurements support dose-response analysis and hit confirmation in screening campaigns targeting axon integrity.
Why are replication requirements essential for cross-functional collaboration in organoid-based screening?
Replication ensures that axon bundle formation is consistent across wells, chips, and experiments, which is critical for generating reliable data shared between biology, screening, and informatics teams. Standardized replication reduces variability and increases confidence in data used for go/no-go decisions.
What statistical analysis capabilities are required to interpret axon bundle formation data before implementation?
The ability to quantify axon length, bundle formation rate, and marker expression enables application of statistical tests such as t-tests or ANOVA to compare control and treatment groups. These analyses are necessary to determine significant differences in axon phenotype and support data-driven advancement decisions.
Chapters in this video
0:05
Introduction
0:47
Photolithographic SU-8 Mold Fabrication
1:59
Polydimethlysiloxane (PDMS) Microfluidic-Based Tissue Culture Chip Fabrication
2:43
PDMS Chip Preparation for Motor Nerve Organoid (MNO) Formation
3:40
Induced Pluripotent Stem (iPS) Cell Differentiation
6:39
Motor Nerve Organoid Formation
7:57
Results
9:15
Conclusion
